PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening

Human epidermal growth factor receptor (EGFR) 2 (HER2) is overexpressed/amplified in about 25% of all breast cancers, and EGFR is overexpressed in up to 76% and amplified in up to 24% of triple-negative breast cancers (TNBC). Here, we aimed to identify inhibitors that may enhance the anti-tumor acti...

全面介紹

書目詳細資料

發表在:	Biomedicines
Main Authors:	Jangsoon Lee, Huey Liu, Troy Pearson, Toshiaki Iwase, Jon Fuson, Alshad S. Lalani, Lisa D. Eli, Irmina Diala, Debu Tripathy, Bora Lim, Naoto T. Ueno
格式:	Article
語言:	英语
出版:	MDPI AG 2021-06-01
主題:	neratinib HER2-positive breast cancer triple-negative breast cancer RNAi screening synergistic effect
在線閱讀:	https://www.mdpi.com/2227-9059/9/7/740